Mutant Membrane Protein Selection for Detergent Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The stability of eukaryotic membrane proteins, particularly when removed from their native membrane environment, is low, making them difficult to crystallize and study for drug development due to poor stability in detergent solutions, which restricts the range of conditions that can be explored without denaturation or precipitation.
Innovation Solution
A method is developed to select mutant membrane proteins with increased stability by exposing them to a membrane destabilizing agent, such as detergents, and determining their stability in situ, allowing for the identification of mutants with enhanced stability compared to their parent proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If eukaryotic membrane proteins are removed from their native membrane environment for study, then they can be purified and crystallized, but their stability in detergent solutions becomes poor, leading to denaturation or precipitation
Solution Approach 1:
The patent applies parameter changes by systematically varying amino acid residues at specific positions in the membrane protein sequence to identify mutations that enhance detergent stability. This involves changing the chemical parameters (amino acid composition) to achieve improved stability while maintaining the protein's ability to be purified and crystallized.
Solution Approach 2:
The patent employs preliminary action by performing in-situ stability screening assays on mutant libraries before full purification and crystallization attempts. This preliminary screening identifies stable mutants early in the process, preventing wasted effort on unstable proteins that would denature during subsequent purification steps.
2Adaptability or versatility
If the range of conditions is expanded to explore crystallization possibilities, then structure determination becomes possible, but the poor stability of eukaryotic membrane proteins restricts the conditions that can be explored
Solution Approach 1:
The patent uses parameter changes to modify the protein's intrinsic properties through mutagenesis, creating variants with enhanced stability that can tolerate a broader range of crystallization conditions. This allows exploration of diverse pH, temperature, and detergent conditions that would otherwise be inaccessible.
Solution Approach 2:
The patent applies beforehand cushioning by introducing stabilizing mutations prior to exposing the protein to challenging crystallization conditions. These pre-introduced mutations act as a buffer or cushion against denaturation, allowing the protein to withstand conditions that would normally cause instability.
3Reliability
If human membrane proteins are targeted for structure determination to aid drug development, then therapeutic relevance is improved, but their instability in detergent solutions makes them difficult to study
Solution Approach 1:
The patent applies parameter changes by mutating specific amino acid residues in human membrane proteins to enhance their detergent stability. This allows the retention of therapeutically relevant human protein sequences while modifying stability parameters to enable purification and structural studies.
Solution Approach 2:
The patent uses copying by creating mutant versions of human membrane proteins that replicate the therapeutic relevance of the native protein while copying in additional stabilizing features through mutagenesis. These mutant copies can be studied structurally while maintaining pharmacological relevance.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
A method for selecting a membrane protein with increased stability, the method comprising: a) providing one or more mutants of a parent membrane protein in a membrane- containing composition, wherein the one or more mutants are exposed to an amount of a membrane destabilising agent which is effective to destabilise the parent membrane protein in-situ, b) determining whether the or each mutant membrane protein has increased stability with respect to its structure and/or a biological activity compared to the stability of the parent membrane protein with respect to its structure and/or the same biological activity, and c) selecting the one or more mutants which have increased stability compared to the stability of the parent membrane protein.